The Second Generation Antibody-Drug Conjugate SYD985 Overcomes Resistances to T-DM1

Trastuzumab emtansine (T-DM1) and ribociclib, an oral inhibitor of cyclin dependent kinase 4 and 6 (CDK 4/6), for patients with metastatic HER2-positive breast cancer.

(2019) Laura Spring et al.   JOURNAL OF CLINICAL ONCOLOGY

Neutralization of BCL-2/XL Enhances the Cytotoxicity of T-DM1 In Vivo

(2019) Jason J. Zoeller et al.   MOLECULAR CANCER THERAPEUTICS

Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study

(2019) Udai Banerji et al.   LANCET ONCOLOGY

Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer

(2019) Francis W. Hunter et al.   BRITISH JOURNAL OF CANCER

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

(2019) Shanu Modi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion

(2018) Mario Mauthe et al.   Autophagy

Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer Cells

(2018) Guangmin Li et al.   MOLECULAR CANCER THERAPEUTICS

A phase I expansion cohorts study of SYD985 in heavily pretreated patients with HER2-positive or HER2-low metastatic breast cancer.

(2018) Cristina Saura et al.   JOURNAL OF CLINICAL ONCOLOGY

DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance

(2017) Naoki Takegawa et al.   INTERNATIONAL JOURNAL OF CANCER

Caveolae-Mediated Endocytosis as a Novel Mechanism of Resistance to Trastuzumab Emtansine (T-DM1)

(2017) Matthew Sung et al.   MOLECULAR CANCER THERAPEUTICS

Tumor Cells Chronically Treated with a Trastuzumab-Maytansinoid Antibody-Drug Conjugate Develop Varied Resistance Mechanisms but Respond to Alternate Treatments

(2015) F. Loganzo et al.   MOLECULAR CANCER THERAPEUTICS

The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers

(2015) M. M. C. van der Lee et al.   MOLECULAR CANCER THERAPEUTICS

Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody–Drug Conjugate SYD985

(2015) Ronald C. Elgersma et al.   MOLECULAR PHARMACEUTICS

Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies

(2015) Rocio Vicario et al.   PLoS One

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial

(2014) Ian E Krop et al.   LANCET ONCOLOGY

Preclinical Profile of the HER2-Targeting ADC SYD983/SYD985: Introduction of a New Duocarmycin-Based Linker-Drug Platform

(2014) W. Dokter et al.   MOLECULAR CANCER THERAPEUTICS

‘How can I halt thee?’ The puzzles involved in autophagic inhibition

(2014) V. Vinod et al.   PHARMACOLOGICAL RESEARCH

Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy

(2013) G. D. L. Phillips et al.   CLINICAL CANCER RESEARCH

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

(2012) Sunil Verma et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

Small-Molecule Multidrug Resistance-Associated Protein 1 Inhibitor Reversan Increases the Therapeutic Index of Chemotherapy in Mouse Models of Neuroblastoma

(2009) C. A. Burkhart et al.   CANCER RESEARCH

Loss of HER2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival Outcomes

(2009) E. A. Mittendorf et al.   CLINICAL CANCER RESEARCH

Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate

(2008) G. D. Lewis Phillips et al.   CANCER RESEARCH